Today, we celebrate #InternationalClinicalTrialsDay and look back at all the clinical trials that were possible from your support over the past year. buff.ly/3UFz7Ex

Clinical trials are imperative to improving health outcomes. They provide the robust evidence that enables us to inform and improve standard of care. In doing so, together we can save countless lives of those with gynaecological cancer. #InternationalClinicalTrialsDay

Tumor Marker #MedEd #MedTwitter #tumormarker

The 5th talk in the UNSW-USYD Big Ideas Oncology seminar series will be conducted by Omico's very own Founder and Chief Science and Strategy Officer, Professor DM Thomas on the 30th September at 12:30-13:30pm (AEST)! Register your in person and online attendance here:

Looking forward to learning more about the impact of novel targets to this pathway. PRMT5i vs MAT2Ai anyone? Servier Pharmaceuticals Pathway well explained at #ESMO24 by Adrian Sacher, M.D.. Omico Australia supported trial in progress🇦🇺

MT-302 has shown preclinical safety and efficacy signals in patients with metastatic epithelial tumors and may change the treatment paradigm for this population, particularly for those with tumors that express TROP2. Charlotte Lemech Scientia Clinical Research (Sydney, Australia) #oncology onclive.com/view/mt-302-un…

Charlotte Lemech, MBBS, discusses the mechanism of action of MT-302, as well as the aims of the MYE Symphony trial and its potential future implications. Charlotte Lemech Scientia Clinical Research (Sydney, Australia) #oncology onclive.com/view/mt-302-un…

We are all about #GCP here at Scientia! Charlotte Lemech

One of our medical oncologists Jᴏᴇ Wᴇɪ has been busy at #ACORD24 workshop this week learning all about #clinicaltrial #protocoldevelopment with inspiring thought leaders in this area. 💡⚡️Looking forward to seeing his new skills in action!

If you have completed chemotherapy in past 3 to 15 months, and have CIPN as a result, then you might be able to participate in our new study. Contact our Recruitment Team on 1800 727 874, or email [email protected], or message us directly here.

Wonderful to host our international guests at our world class facility in advance of AusBiotech in Melbourne! 🇦🇺🇯🇵🇰🇷 #collaboration

What kinds of patients are referred for #phase1oncology trials at Scientia Clinical Research (Sydney, Australia)? Christina Teng presents #AGITG24 poster showing >50% patients with @GIcancer enrolled on trials come from outside metro Sydney. 👏 #babysteps for equity to trial access 📈

Your cancer may be rare, but you are not alone. Connect with others who really understand at one of our upcoming support groups, via phone or videoconference. Email [email protected] to request to join.

As part of the NECTA group of oncology phase1 sites, we are pleased to share the invitation for NECTA’s Drug Development Meeting 2025, here in Sydney, on 28th March 2025. Register now: lnkd.in/ggTsiCG9

Happy Chinese New Year to all our volunteers and partners, here in Australia and in SE Asia and China! 2025 is the Year of the Snake, an animal which symbolises good luck, rebirth and regality, but also mystery and transformation. 新年快乐 Happy New Year 🎉 #chinesenewyear

Medical director Charlotte Lemech represented Scientia Clinical Research (Sydney, Australia) at this supercharged meeting. Our oncologists are already getting excited by the BioNTech SE development pipeline! Jᴏᴇ Wᴇɪ Christina Teng Looking forward to another fruitful collaboration in 2025.

Partner with 🇦🇺 companies to have clinical trials underway in under 6 weeks! Deputy CG Steven was part of a full house at the Investment NSW business matching lunch to link up NSW companies Scientia Clinical Research (Sydney, Australia), Paratus Clinical & Novotech with #NammaBengaluru’s biotech ecosystem.

Join us this month and learn about the latest developments in early phase oncology drug dev across AU and the world! Registrations still open and free for academic/NFP attendees. events.zoom.us/ev/AjHf5uaEMrC…

We are at APOS today discussing how to streamline collaboration between NSW oncology clinicians, trial sites, sponsors, diagnostic partners to deliver better care for patients. #OMICO #UNSW #rarecancersaustralia

Great morning of inspiring and diverse talks on science and clinical trials at our annual NECTA Drug Dev Meeting 2025! #drugdev #global #collaboration